Revelation Biosciences(REVB) - 2023 Q4 - Annual Results

The changes in net cash used for operating activities and the increase in net loss for the three months ended December 31, 2023 as compared to December 31, 2022 was primarily due to pre-clinical costs and clinical preparation costs primarily for programs GEM- SSI and GEM-AKI. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 San Diego, CA – March 22, 2024 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), ...